165 related articles for article (PubMed ID: 9588725)
1. Systemic therapy in melanoma.
Nathan FE; Mastrangelo MJ
Semin Surg Oncol; 1998 Jun; 14(4):319-27. PubMed ID: 9588725
[TBL] [Abstract][Full Text] [Related]
2. Systemic chemotherapy for metastatic melanoma.
Mc Clay EF; Mastrangelo MJ
Semin Oncol; 1988 Dec; 15(6):569-77. PubMed ID: 2462747
[TBL] [Abstract][Full Text] [Related]
3. Current therapy for malignant melanoma.
Legha SS
Semin Oncol; 1989 Feb; 16(1 Suppl 1):34-44. PubMed ID: 2465575
[TBL] [Abstract][Full Text] [Related]
4. [Chemo-/immunotherapy in advanced malignant melanoma: carboplatin and DTIC or cisplatin, dtic, bcnu and tamoxifen followed by immunotherapy with interleukin 2 and interferon alpha-2a].
Kirchner HH; Atzpodien J; Poliwoda H
Med Klin (Munich); 1996 Apr; 91 Suppl 3():44-9. PubMed ID: 8692119
[TBL] [Abstract][Full Text] [Related]
5. Chemoimmunotherapy of advanced malignant melanoma: sequential administration of subcutaneous interleukin-2 and interferon-alpha after intravenous dacarbazine and carboplatin or intravenous dacarbazine, cisplatin, carmustine and tamoxifen.
Atzpodien J; Lopez Hänninen E; Kirchner H; Franzke A; Körfer A; Volkenandt M; Duensing S; Schomburg A; Chaitchik S; Poliwoda H
Eur J Cancer; 1995 Jun; 31A(6):876-81. PubMed ID: 7646914
[TBL] [Abstract][Full Text] [Related]
6. Dacarbazine-based chemotherapy for metastatic melanoma: thirty-year experience overview.
Serrone L; Zeuli M; Sega FM; Cognetti F
J Exp Clin Cancer Res; 2000 Mar; 19(1):21-34. PubMed ID: 10840932
[TBL] [Abstract][Full Text] [Related]
7. Combination chemotherapy for disseminated malignant melanoma.
Abbott KL; Harman GS
Anticancer Drugs; 1995 Aug; 6(4):489-97. PubMed ID: 7579552
[TBL] [Abstract][Full Text] [Related]
8. Chemotherapy and chemoimmunotherapy in disseminated malignant melanoma.
Garbe C
Melanoma Res; 1993 Aug; 3(4):291-9. PubMed ID: 7693093
[TBL] [Abstract][Full Text] [Related]
9. Chemotherapy for advanced malignant melanoma.
Buzaid AC; Murren J
Int J Clin Lab Res; 1992; 21(3):205-9. PubMed ID: 1591369
[TBL] [Abstract][Full Text] [Related]
10. Rationale for intergroup trial E-3695 comparing concurrent biochemotherapy with cisplatin, vinblastine, and DTIC alone in patients with metastatic melanoma.
Flaherty LE
Cancer J Sci Am; 2000 Feb; 6 Suppl 1():S15-20. PubMed ID: 10685653
[TBL] [Abstract][Full Text] [Related]
11. The treatment of disseminated malignant melanoma with special reference to the role of interferons, vinca alkaloids and tamoxifen.
Bezwoda WR
Cancer Treat Rev; 1997 Jan; 23(1):17-34. PubMed ID: 9189179
[TBL] [Abstract][Full Text] [Related]
12. Single-agent DTIC versus combination chemotherapy with or without immunotherapy in metastatic melanoma: a meta-analysis of 3273 patients from 20 randomized trials.
Huncharek M; Caubet JF; McGarry R
Melanoma Res; 2001 Feb; 11(1):75-81. PubMed ID: 11254118
[TBL] [Abstract][Full Text] [Related]
13. Randomized phase II trial of BCDT [carmustine (BCNU), cisplatin, dacarbazine (DTIC) and tamoxifen] with or without interferon alpha (IFN-alpha) and interleukin (IL-2) in patients with metastatic melanoma.
Johnston SR; Constenla DO; Moore J; Atkinson H; A'Hern RP; Dadian G; Riches PG; Gore ME
Br J Cancer; 1998 Apr; 77(8):1280-6. PubMed ID: 9579834
[TBL] [Abstract][Full Text] [Related]
14. Randomized, double-blind, placebo-controlled trial comparing the response rates of carmustine, dacarbazine, and cisplatin with and without tamoxifen in patients with metastatic melanoma. National Cancer Institute of Canada Clinical Trials Group.
Rusthoven JJ; Quirt IC; Iscoe NA; McCulloch PB; James KW; Lohmann RC; Jensen J; Burdette-Radoux S; Bodurtha AJ; Silver HK; Verma S; Armitage GR; Zee B; Bennett K
J Clin Oncol; 1996 Jul; 14(7):2083-90. PubMed ID: 8683240
[TBL] [Abstract][Full Text] [Related]
15. Biochemotherapy for melanoma.
Philip PA; Flaherty LE
Curr Oncol Rep; 2000 Jul; 2(4):314-21. PubMed ID: 11122859
[TBL] [Abstract][Full Text] [Related]
16. Metastatic melanoma.
Sun W; Schuchter LM
Curr Treat Options Oncol; 2001 Jun; 2(3):193-202. PubMed ID: 12057119
[TBL] [Abstract][Full Text] [Related]
17. Treatment of metastatic malignant melanoma.
Atallah E; Flaherty L
Curr Treat Options Oncol; 2005 May; 6(3):185-93. PubMed ID: 15869730
[TBL] [Abstract][Full Text] [Related]
18. A randomized phase III study comparing dacarbazine, BCNU, cisplatin and tamoxifen with dacarbazine and interferon in advanced melanoma.
Middleton MR; Lorigan P; Owen J; Ashcroft L; Lee SM; Harper P; Thatcher N
Br J Cancer; 2000 Mar; 82(6):1158-62. PubMed ID: 10735499
[TBL] [Abstract][Full Text] [Related]
19. Phase II trial of subcutaneous interleukin-2, subcutaneous interferon-alpha, intravenous combination chemotherapy, and oral tamoxifen in the treatment of metastatic melanoma: final results of cancer biotherapy research group 94-11.
Dillman RO; Soori G; Wiemann MC; Schulof R; Dobbs TW; Ruben RH; DePriest CB; Church C
Cancer Biother Radiopharm; 2000 Oct; 15(5):487-94. PubMed ID: 11155820
[TBL] [Abstract][Full Text] [Related]
20. Systemic treatments for advanced cutaneous melanoma.
Anderson CM; Buzaid AC; Legha SS
Oncology (Williston Park); 1995 Nov; 9(11):1149-58; discussion 1163-4, 1167-8. PubMed ID: 8703684
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
